Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CANF Can-Fite BioPharma	$0.66 -0.8%	$0.90	$0.63 ▼ $3.12	$2.34M	1.02	209,631 shs	91,392 shs
NLSP NLS Pharmaceutics	$2.63 -5.4%	$2.29	$1.30 ▼ $7.37	$9.47M	0.15	1.05 million shs	155,805 shs
PRTG Portage Biotech	$9.11 +2.8%	$6.56	$2.81 ▼ $23.01	$9.57M	0.24	588,776 shs	15,712 shs
SNGX Soligenix	$3.38 +0.6%	$1.95	$1.09 ▼ $6.23	$14.50M	1.95	4.44 million shs	593,116 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CANF Can-Fite BioPharma	+1.37%	-1.48%	-35.02%	-35.90%	-70.66%
NLSP NLS Pharmaceutics	+3.73%	+6.51%	+29.30%	+50.27%	+1,407.59%
PRTG Portage Biotech	+7.26%	+0.68%	+51.97%	+12.29%	+234.34%
SNGX Soligenix	-6.93%	+14.29%	+138.30%	+85.64%	-24.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CANF Can-Fite BioPharma	2.0272 of 5 stars	3.5	2.0	0.0	0.0	1.1	0.0	1.3
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRTG Portage Biotech	0.9261 of 5 stars	0.0	5.0	0.0	0.0	1.4	1.7	0.0
SNGX Soligenix	2.1621 of 5 stars	3.5	2.0	0.0	0.0	2.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CANF Can-Fite BioPharma	3.00	Buy	$14.00	2,018.00% Upside
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A
PRTG Portage Biotech	0.00	N/A	N/A	N/A
SNGX Soligenix	3.00	Buy	$6.00	77.51% Upside

Current Analyst Ratings Breakdown

Latest CANF, PRTG, SNGX, and NLSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/16/2025	SNGX Soligenix	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $6.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CANF Can-Fite BioPharma	$674K	3.47	N/A	N/A	$1.76 per share	0.38
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	($0.37) per share	N/A
PRTG Portage Biotech	N/A	N/A	N/A	N/A	($0.79) per share	N/A
SNGX Soligenix	$120K	120.84	N/A	N/A	$0.43 per share	7.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CANF Can-Fite BioPharma	-$7.63M	-$1.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	-$1.98M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PRTG Portage Biotech	-$6.77M	-$41.65	N/A	∞	N/A	N/A	N/A	N/A	8/26/2025 (Estimated)
SNGX Soligenix	-$8.27M	-$3.80	N/A	N/A	N/A	N/A	-274.76%	-129.20%	N/A

Latest CANF, PRTG, SNGX, and NLSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	SNGX Soligenix	-$0.79	-$0.82	-$0.03	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CANF Can-Fite BioPharma	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A
PRTG Portage Biotech	N/A	N/A	N/A	N/A	N/A
SNGX Soligenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CANF Can-Fite BioPharma	N/A	2.93	N/A
NLSP NLS Pharmaceutics	N/A	2.69	2.69
PRTG Portage Biotech	N/A	2.02	2.02
SNGX Soligenix	N/A	1.47	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CANF Can-Fite BioPharma	21.00%
NLSP NLS Pharmaceutics	N/A
PRTG Portage Biotech	13.36%
SNGX Soligenix	3.60%

Insider Ownership

Company	Insider Ownership
CANF Can-Fite BioPharma	0.80%
NLSP NLS Pharmaceutics	16.40%
PRTG Portage Biotech	42.07%
SNGX Soligenix	3.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CANF Can-Fite BioPharma	8	3.54 million	N/A	Not Optionable
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable
PRTG Portage Biotech	6	1.05 million	608,000	Optionable
SNGX Soligenix	20	4.29 million	4.16 million	Not Optionable

CANF, PRTG, SNGX, and NLSP Headlines

Recent News About These Companies

Soligenix Inc. Reports Q2 2025 Earnings Loss

August 22 at 11:58 AM | msn.com

Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky

August 21 at 6:37 AM | finance.yahoo.com

Small Cap Stocks To Follow Today - August 18th

August 20 at 3:03 AM | americanbankingnews.com

Soligenix (NASDAQ:SNGX) Cut to Strong Sell at Wall Street Zen

August 19 at 2:27 AM | americanbankingnews.com

Why Is Soligenix Stock Soaring On Monday?

August 18, 2025 | benzinga.com

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

August 18, 2025 | msn.com

Soligenix stock soars after FDA grants orphan drug designation

August 18, 2025 | za.investing.com

Soligenix Shares Surge After FDA Grants Orphan Drug Status

August 18, 2025 | msn.com

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

August 18, 2025 | prnewswire.com

Soligenix Faces Nasdaq Non-Compliance Notice

August 16, 2025 | msn.com

SOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

August 14, 2025 | finanznachrichten.de

Soligenix receives FDA orphan designation for dusquetide

August 14, 2025 | msn.com

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

August 14, 2025 | prnewswire.com

Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy

August 8, 2025 | finance.yahoo.com

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

August 8, 2025 | globenewswire.com

Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...

August 7, 2025 | gurufocus.com

Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...

August 7, 2025 | gurufocus.com

Soligenix Completes Phase 2a Study for SGX945

August 6, 2025 | theglobeandmail.com

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

August 5, 2025 | finance.yahoo.com

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 4, 2025 | newswire.ca

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF, PRTG, SNGX, and NLSP Company Descriptions

Can-Fite BioPharma NYSE:CANF

$0.66 -0.01 (-0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.15%)

As of 06:02 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

NLS Pharmaceutics NASDAQ:NLSP

$2.63 -0.15 (-5.40%)

Closing price 04:00 PM Eastern

Extended Trading

$2.65 +0.02 (+0.76%)

As of 07:09 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Portage Biotech NASDAQ:PRTG

$9.11 +0.25 (+2.82%)

Closing price 04:00 PM Eastern

Extended Trading

$9.48 +0.37 (+4.01%)

As of 06:56 PM Eastern

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Soligenix NASDAQ:SNGX

$3.38 +0.02 (+0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$3.34 -0.03 (-1.04%)

As of 07:16 PM Eastern

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time